Search research articles
Contact Us
Filters
Showing results (61-70 of 64) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 64 results.
Respiratory Investigation
|
May 30, 2024
Predictors of exacerbation in Japanese patients with severe asthma: Analysis of the severe asthma research program (Okayama-SARP) cohort
Hisao Higo, Akihiko Taniguchi, Satoru Senoo, et al.
Therapeutic Advances in Medical Oncology
|
August 4, 2022
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
Shigeru Tanzawa, Tomonori Makiguchi, Sadatomo Tasaka, et al.
Therapeutic Advances in Medical Oncology
|
December 26, 2022
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis
Hisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, et al.
Therapeutic Advances in Medical Oncology
|
March 15, 2021
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)
Shigeru Tanzawa, Sunao Ushijima, Kazuhiko Shibata, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 64) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 64 results.
Respiratory Investigation
|
May 30, 2024
Predictors of exacerbation in Japanese patients with severe asthma: Analysis of the severe asthma research program (Okayama-SARP) cohort
Hisao Higo, Akihiko Taniguchi, Satoru Senoo, et al.
Therapeutic Advances in Medical Oncology
|
August 4, 2022
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
Shigeru Tanzawa, Tomonori Makiguchi, Sadatomo Tasaka, et al.
Therapeutic Advances in Medical Oncology
|
December 26, 2022
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis
Hisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, et al.
Therapeutic Advances in Medical Oncology
|
March 15, 2021
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)
Shigeru Tanzawa, Sunao Ushijima, Kazuhiko Shibata, et al.
Page
of 7